# NGL Fine-Chem (NSE: NGLFINE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NGLFINE · Pivot · prices to 22 Oct 2026

NGL Fine-Chem (NSE: NGLFINE) closed at ₹2,717.20 on 22 Oct 2026, up 3.00% on the day. With a market capitalisation of ₹1,679 Cr, it ranks 1211th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 34.8× trailing earnings, against a return on equity of 14.6% in FY26. Over the past year the share price has risen 80.2%. Its 52-week range is ₹1,271.00 (19 Dec 2025) to ₹3,602.00 (12 Aug 2026); the last close is 24.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹149 Cr (+57.1% year on year) and net profit ₹13 Cr (+2,398.1%), on a consolidated basis. Promoters held 72.49% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,717.20 |
| Market cap | ₹1,679 Cr |
| P/E (trailing) | 34.8 |
| ROE | 14.6% (FY26) |
| ROCE | 17.2% (FY26) |
| Debt to equity | 0.33 |
| 52-week high | ₹3,602.00 (12 Aug 2026) |
| 52-week low | ₹1,271.00 (19 Dec 2025) |
| 1-year return | +80.2% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹149 Cr | +57.1% | ₹13 Cr | +2,398.1% | ₹21.83 |
| Q3 FY26 | ₹128 Cr | +43.1% | ₹16 Cr | +1,125.8% | ₹25.40 |
| Q2 FY26 | ₹120 Cr | +28.6% | ₹10 Cr | −1.8% | ₹15.58 |
| Q1 FY26 | ₹104 Cr | +14.8% | ₹9 Cr | +0.2% | ₹14.96 |
| Q4 FY25 | ₹95 Cr | −4.8% | ₹1 Cr | −95.6% | ₹0.88 |
| Q3 FY25 | ₹89 Cr | +1.3% | ₹1 Cr | −87.2% | ₹2.07 |
| Q2 FY25 | ₹93 Cr | +16.6% | ₹10 Cr | −6.4% | ₹15.88 |
| Q1 FY25 | ₹91 Cr | +27.7% | ₹9 Cr | +8.3% | ₹14.92 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹368 Cr | ₹21 Cr |
| FY24 | ₹339 Cr | ₹41 Cr |
| FY23 | ₹278 Cr | ₹21 Cr |
| FY22 | ₹318 Cr | ₹50 Cr |
| FY21 | ₹258 Cr | ₹57 Cr |
| FY20 | ₹152 Cr | ₹8 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.49%
- Foreign institutions: 0.05%
- Domestic institutions: 0.02%
- Non-institutions: 27.43%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,165.00 | ₹1,842 Cr | 32 | — |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹885.70 | ₹1,828 Cr | 28.4 | — |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹26.21 | ₹1,715 Cr | 58.2 | — |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹510.75 | ₹1,657 Cr | 16.5 | — |
| [Jupiter Life Line Hospitals](https://app.pivotnow.in/stock/JLHL) | ₹244.75 | ₹1,605 Cr | 8.3 | — |

## Questions and answers

### What is the share price of NGL Fine-Chem today?

NGL Fine-Chem (NSE: NGLFINE) last closed at ₹2,717.20 on 22 Oct 2026. Its 52-week high is ₹3,602.00 and its 52-week low is ₹1,271.00.

### What is the market cap of NGL Fine-Chem?

NGL Fine-Chem's market capitalisation is ₹1,679 Cr (₹1,679 Cr) at the 22 Oct 2026 close, ranking 1211th among the NSE companies Pivot tracks.

### What is the P/E ratio of NGL Fine-Chem?

NGL Fine-Chem trades at a trailing P/E of 34.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 28.4.

### What is the ROE and ROCE of NGL Fine-Chem?

Return on equity was 14.6% in FY26 and return on capital employed was 17.2% in FY26 (consolidated figures).

### Is NGL Fine-Chem a debt-free company?

No. NGL Fine-Chem's debt-to-equity ratio was 0.33 in FY26, with total debt of ₹56 Cr.

### What were NGL Fine-Chem's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), NGL Fine-Chem reported revenue of ₹149 Cr, +57.1% year on year, and net profit of ₹13 Cr, +2,398.1% year on year.

### How has NGL Fine-Chem stock performed over the last year?

NGL Fine-Chem's share price has risen 80.2% over the past year, −15.4% over three months and −0.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of NGL Fine-Chem?

As of 30 Jun 2026: promoters 72.49%, foreign institutions 0.05%, domestic institutions 0.02%, non-institutions 27.43%.

### Who are NGL Fine-Chem's competitors?

The listed Pharma & Healthcare companies closest to NGL Fine-Chem by market cap are Hester Biosciences, Windlas Biotech, Titan Biotech, Fischer Medical Ventures, Krsnaa Diagnostics and Jupiter Life Line Hospitals.

### Is NGL Fine-Chem a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out NGL Fine-Chem's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NGLFINE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.